STOK stock forecast, quote, news & analysis
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine... Show more
Stoke Therapeutics (STOK) Stock Analysis: Pipeline Momentum Builds
Key Takeaways
- STOK shares have surged over 340% in the past year amid positive clinical data for zorevunersen in Dravet syndrome.
- Phase 3 EMPEROR trial enrollment expected to complete in Q2 2026, with data readout mid-2027 supporting NDA filing.
- 2025 revenue reached $184.4M from Biogen collaboration, cash runway into mid-2028.
- Analysts maintain Strong Buy ratings with average price target around $45.
- Recent NEJM publication highlights potential disease-modifying effects in Dravet syndrome.
- Insider sales noted amid rally, but institutional interest remains strong.
Current Market Snapshot
Stoke Therapeutics (STOK) has experienced significant volatility in recent trading sessions, reflecting biotech sector dynamics and pipeline progress. The stock has climbed substantially over the past year, trading near the upper end of its 52-week range amid optimism around its lead candidate zorevunersen. Market cap hovers around $1.9 billion, with shares showing resilience despite broader market pressures. Investor focus centers on clinical milestones and partnership revenue, driving heightened trading activity in the latest market cycle. Price action underscores sensitivity to news flow, with upward momentum tied to positive data readouts and trial updates.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of the platform's top-performing AI trading bots, drawn from hundreds of agents that analyze and trade thousands of tickers across stocks, ETFs, and other assets. Only the most suitable bots for prevailing market conditions—factoring in volatility, sector momentum, and risk-adjusted returns—earn a spot in this dynamic lineup, currently featuring 25 standout performers out of 351 total bots. These agents employ diverse strategies, from short-term 5-minute scalps to 60-minute swings, with impressive stats like annualized returns up to 123%, win rates exceeding 87% in some cases, and profit factors optimized for sectors like semiconductors, energy, and aerospace. For instance, bots targeting volatile ETFs boast 70-80% win rates over hundreds of trades, while multi-ticker strategies in oil and tech deliver 18-95% annualized gains with drawdowns under 10%. This variety allows traders to match bots to their style, whether aggressive growth or conservative hedging. Explore the Trending AI Robots page to identify those aligned with current trends and potentially enhance your STOK trading approach.
Recent Developments Driving STOK Price Action
Stoke Therapeutics, a biotech firm developing RNA-based medicines to upregulate protein expression for severe genetic diseases, has seen its stock price action dominated by pipeline advancements and financial updates over recent weeks. The lead program, zorevunersen (in partnership with Biogen), targets Dravet syndrome, a rare epilepsy disorder, and has fueled much of the rally.
In early March 2026, The New England Journal of Medicine published long-term data from the Phase 1/2 studies MONARCH and ADMIRAL, demonstrating zorevunersen's potential disease-modifying effects. The results showed durable seizure reductions and improvements in cognition and behavior up to two years, boosting investor sentiment and contributing to the stock's 340% one-year gain. This publication reinforced the rationale for the ongoing Phase 3 EMPEROR trial, with accelerated timelines announced earlier: enrollment completion now slated for Q2 2026 across 150 patients in the US, UK, Japan, and expanding to Europe, targeting mid-2027 data readout to support a rolling NDA filing in H1 2027.
Financially, the company's 10-K filing revealed 2025 full-year revenue of $184.4 million, primarily from Biogen collaboration milestones, narrowing net losses and extending cash runway to mid-2028 with approximately $390 million on hand as of late 2025. Quarterly fluctuations persisted, with Q4 revenue at $1.4 million and EPS of -$0.97, but trailing 12-month profitability highlighted partnership strength.
Analyst enthusiasm surged, with firms like Canaccord raising targets to $60 (from $36), Wedbush to $38, and Guggenheim reiterating Buy ratings, consensus around $45 amid Strong Buy outlook. These upgrades directly correlated with price spikes, as seen in mid-March gains.
Pipeline expansion added tailwinds: In February, Stoke dosed the first patient in the Phase 1 trial of STK-002 for autosomal dominant optic atrophy (ADOA), diversifying beyond Dravet. Inducement grants in March signaled hiring for growth.
Offsetting some momentum, insider sales by the CMO ($457K) and Chair ($174K) amid the rally introduced caution, though typical in biotech post-rallies. A shelf registration filing raised dilution fears but supports funding needs. Macro factors like biotech sector rotation and rare disease funding trends amplified reactions, with STOK outperforming peers on data catalysts.
Overall, these events linked directly to price surges on positive news and minor pullbacks on sales/filings, underscoring STOK's event-driven profile.
2026 Outlook and Key Factors to Monitor
As Stoke Therapeutics advances through 2026, attention will center on Phase 3 EMPEROR enrollment completion in Q2, setting the stage for mid-2027 topline data. Investors should track patient recruitment momentum across global sites, including new European activations, and any FDA feedback on expedited pathways under Breakthrough Therapy Designation. The Biogen collaboration remains pivotal, with milestone payments and revenue recognition impacting cash flow amid ongoing R&D spend around $138 million annually.
STK-002's Phase 1 progress in ADOA offers pipeline diversification, while manufacturing scale-up and regulatory preparations for potential 2027 launch warrant scrutiny. Competitive landscape in genetic epilepsies and optic neuropathies, plus broader RNA therapeutics trends, could influence positioning. Risks include trial delays, safety signals, or funding needs despite mid-2028 runway. Macro biotech funding environment and rare disease policy shifts will also play roles. Balanced monitoring of these operational, regulatory, and financial drivers will be essential for assessing long-term value.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
STOK in upward trend: 10-day moving average crossed above 50-day moving average on April 14, 2026
The 10-day moving average for STOK crossed bullishly above the 50-day moving average on April 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on April 07, 2026. You may want to consider a long position or call options on STOK as a result. In of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for STOK just turned positive on April 08, 2026. Looking at past instances where STOK's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .
STOK moved above its 50-day moving average on April 07, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where STOK advanced for three days, in of 306 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STOK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
STOK broke above its upper Bollinger Band on April 08, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. STOK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.262) is normal, around the industry mean (26.679). P/E Ratio (48.338) is within average values for comparable stocks, (45.954). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.776). Dividend Yield (0.000) settles around the average of (0.034) among similar stocks. P/S Ratio (11.990) is also within normal values, averaging (325.704).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STOK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the research and development of treatments for genetic diseases.
Industry Biotechnology